Sanofi–Translate Bio COVID-19 vaccine
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | MRT5500, VAW00001 |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
|
| COVID-19 portal |
The Sanofi–Translate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio.[3][4] The development was stopped in September 2021.[5]
- ^ Abboud L (28 September 2021). "Sanofi stops development of Covid vaccine based on mRNA technology". Financial Times.
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. Archived from the original on 9 October 2021. Retrieved 20 March 2021.
- ^ "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". United States National Library of Medicine. Retrieved 20 March 2021.
- ^ "Sanofi drops plans for messenger RNA vaccine against virus". Associated Press. 28 September 2021. Archived from the original on 14 October 2021. Retrieved 7 October 2021.